InspireMD (NYSE:NSPR) Now Covered by StockNews.com

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research report released on Wednesday. The firm issued a sell rating on the stock.

InspireMD Trading Up 4.4 %

Shares of NSPR opened at $2.00 on Wednesday. The firm has a market cap of $46.80 million, a PE ratio of -1.85 and a beta of 0.83. The firm has a fifty day simple moving average of $2.37 and a two-hundred day simple moving average of $2.66. InspireMD has a 1-year low of $1.03 and a 1-year high of $3.85.

InspireMD (NYSE:NSPR) last announced its earnings results on Wednesday, March 6th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $1.76 million during the quarter, compared to analyst estimates of $1.65 million. InspireMD had a negative net margin of 320.97% and a negative return on equity of 55.71%. During the same period in the previous year, the business earned ($0.60) EPS. As a group, research analysts forecast that InspireMD will post -0.61 EPS for the current fiscal year.

Institutional Investors Weigh In On InspireMD

Hedge funds have recently added to or reduced their stakes in the stock. Mesirow Financial Investment Management Inc. bought a new position in InspireMD in the 1st quarter worth $71,000. Avestar Capital LLC bought a new position in shares of InspireMD during the 3rd quarter valued at about $65,000. Finally, McKinley Carter Wealth Services Inc. bought a new position in shares of InspireMD during the 4th quarter valued at about $28,000. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.